Clinical Program Update and projected timelines Brje Darp, VP Development

1
Clinical ProgramUpdate and projected
timelinesBörje Darpö, VP Development
2
Key clinical projects

• TMC435450Completed phase I trial in healthy
  subjects and in HCV patients has shown (AASLD
  Nov 2007)
• Safe and well-tolerated
• Once-daily dosing is achieved
• High set target for viral load reduction in HCV
  patients achieved in phase Ib
• Phase IIa has been initiated

HEPATITIS C

• MIV-701Clinical part of phase I trial completed
• Substantial reduction of biomarker for bone-
  resorption in healthy subjects and
  post-menopausal women
• Partnership anticipated during 2008

Bone disorders

• Lipsovir
• Phase III program near finalization
• Partnership(s) after phase III data

LABIAL HERPES
3
Lipsovir for prevention and treatment of cold
sores

• First drug to
• prevent the development of ulcerative lesions
  (cold sores)
• and
• result in reduced episode duration in patients
  who develop cold sores

hydrocortisone
acyclovir
IP protection
Formulation of the cream
4
Available therapies do not prevent cold sores
4
5
Three of four sufferers express an interestin
Lipsovir
Definitely would buy Probably
would buy Might or might not buy
Probably would not buy
Definitely would not buy
Primary market research 403 (UK) 411 (US)
respondents
6
A billion dollar market
Annual value growth 9
Rx (USD 450m)
Palliative (USD 400m)
OTC (USD 220m)
Annual value growth 12